CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10703 ETCTN A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in β-catenin-mutated Hepatocellular Carcinoma (SAPHIRE) Adult CIRB - Early Phase Emphasis
10707 ETCTN Phase 2 Trial of CBX-12 for Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer Adult CIRB - Early Phase Emphasis
8329 ETCTN A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy Adult CIRB - Early Phase Emphasis
9149 ETCTN Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors Adult CIRB - Late Phase Emphasis
9466 ETCTN Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only) Adult CIRB - Early Phase Emphasis
9571 ETCTN A phase IB study of the combination of AZD6244 hydrogen sulfate (selumetinib) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer Adult CIRB - Early Phase Emphasis
9608 ETCTN A Phase I Trial of ABT-263 (Navitoclax); a Bcl-2 inhibitor; and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors Adult CIRB - Early Phase Emphasis
9653 ETCTN Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder Adult CIRB - Early Phase Emphasis
9671 ETCTN Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders Adult CIRB - Early Phase Emphasis
9672 ETCTN A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus Adult CIRB - Early Phase Emphasis